Table 3.

Summary measures collected from the original publications and their corresponding estimates obtained from the reconstructed individual patient data (IPD).

Treatment(s)	Median PFS		Median OS
	Original	Reconstructed	Original	Reconstructed
Pertuzumab + trastuzumab +   docetaxel	18.7 m	19.0 m	NE	NE
Trastuzumab + docetaxel	12.4 m	12.9 m	37.6 m	37.8 m
Capecitabine + lapatinib	5.9 m	27.7 w (6.4 m)*	NA	30.0 w
Trastuzumab + lapatinib	12.0 w	12.45 w	51.6 w	50.2 w
T-DM1	9.6 m	10.13 m	30.9 m	32.1 m
Trastuzumab + capecitabine	8.2 m	8.7 m	25.5 m	25.4 m

T-DM1: trastuzumab emtansine; PFS: progression-free survival; OS: overall survival; NE: not estimated; NA: not available; m: months; w: weeks.

^*Conversion from weeks to months using online converter (http://www.convertunits.com/from/weeks/to/months).